Back to results
US 2009/0275650 A1Published application
3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof
AssigneeTemple University of the Commonwealth System of Higher Education
InventorsM.V. Ramana Reddy, E. Premkumar Reddy
Life of this patent
Estimating the term…
Abstract
Compounds of Formula I: wherein R1, R2, M, Q and n are as defined herein, are useful as antiproliferative agents including, for example, as anticancer agents.
Claims62
A compound according to Formula I:
- wherein:
- each Q is independently O, S, or NH;
- each R1 is independently selected from the group consisting of halogen, —(C1-C8)hydrocarbyl, —C(═O)Ry, —NRw2, —N(Rw)C(═O)Ry, —N(Rw)C(Rz)C(═O)Ry, —N(Rw)SO2Ry, —N(Rw)(C1-C4)alkylene-CO2Rw, —NO2, —CN, —ORw, —OC(═O)Ry, —OC(Rz)C(═O)Ry, —OSO2Ry—O(C1-C4)alkylene-CO2Rx, —OP(═O)(ORw)2, —O(C2-C6)alkylene-N(CH3)2, —O(C1-C6)haloalkyl, —P(═O)(ORw)2, —SO2N(Rw)Rx, —NHC(═NH)NHRx, —(C1-C6)haloalkyl and heteroalkyl;
- Rw is —H or —(C1-C8)hydrocarbyl;
- Rx is —H, —(C1-C8)hydrocarbyl or —C(═O)(C1-C8)hydrocarbyl;
- Ry is selected from the group consisting of —H, —(C1-C8)hydrocarbyl, —O(C1-C8)hydrocarbyl, substituted phenyl, substituted heterocyclyl(C1-C3)alkyl, heteroaryl(C1-C3)alkyl, —(C2-C10)heteroalkyl, —(C1-C6)haloalkyl, —C(Rz)NHRx, —N(Rw)Rx, —(C1-C3)alkyleneNH2, —(C1-C3)alkyleneN(CH3)2, —(C1-C3)perfluoroalkyleneN(CH3)2, —(C1-C3)alkyleneN+(C1-C3)3, —(C1-C3)alkylene-N+(CH2CH2OH)3, —(C1-C3)alkylene-ORx, —(C1-C4)alkylene-CO2Rx, —(C1-C4)alkylene-CO2N(Rw)Rx, —(C1-C4)alkylene-C(═O)halogen, halo(C1-C3)alkyl and —(C1-C4)perfluoroalkylene-CO2Rx;
- Rz is selected from the group consisting of —H, —(C1-C6)alkyl, —(CH2)3—NH—C(NH2)(═NH), —CH2C(═O)NH2, —CH2COOH, —CH2SH, —(CH2)2C(═O)—NH2, —(CH2)2CO2H, —CH2-(2-imidazolyl), —(CH2)4—NH2, —(CH2)2—S—CH3, phenyl, —CH2-phenyl, —CH2—OH, —CH(OH)—CH3, —CH2-(3-indolyl) and —CH2-(4-hydroxyphenyl);
- each n is independently selected from the group consisting of 0, 1, 2, 3 and 4;
- M is selected from the group consisting of a single bond and (a), (b), and (c):
- A is N or CH;
- R2 is substituted or unsubstituted aryl other than unsubstituted phenyl or substituted or unsubstituted heteroaryl;
- R3 is selected from the group consisting of —H and —(C1-C6)alkyl;
- and
- m is 0 or 1;
- provided that:
- (i) when M is a single bond, then R2 is:
- R1 is other than 7-NRw2 or 7-ORw;
- (ii) when M is a single bond, and Q is O, then R1 is other than 5- or 7-halogen, 5- or 7-(C1-C8)hydrocarbyl, 5- or 7-NO2 or 5-ORw;
- (iii) when M is a single bond, Q is O, and n is 1, then R1 is other than 6-NO2, 6—Cl or 6-Br;
- (iv) when M is (c) and m is O, then R2 is:
- (v) when M is (b), then n is other than O, R1 is other than 7-NRw2, and R2 is other than 4-alkoxyphenyl;
- (vi) when M is (a) and Q is O, then R1 is other than —NRw2 and n is other than 0;
- and
- (vii) when M is (a), Q is S, and n is 1, then R1 is other than 7-ORw or 7-NRw2;
- or a salt of such a compound.
22 more elements
A compound according to Formula II:
- wherein:
- Q is O, S, or NH;
- A is N or CH;
- each R1 is independently selected from the group consisting of halogen, —(C1-C8)hydrocarbyl, —C(═O)Ry, —NRw2, —N(Rw)C(═O)Ry, —N(Rw)C(Rz)C(═O)Ry, —N(Rw)SO2Ry, —N(Rw)(C1-C4)alkylene-CO2Rw, —NO2, —CN, —ORw, —OC(═O)Ry, —OC(Rz)C(═O)Ry, —OSO2Ry—O(C1-C4)alkylene-CO2Rw, —OP(═O)(ORw)2, —O(C2-C6)alkylene-N(CH3)2, —O(C1-C6)haloalkyl, —P(═O)(ORw)2, —SO2N(Rw)Rx, —NHC(═NH)NHRx, —(C1-C6)haloalkyl and heteroalkyl;
- Rw is —H or —(C1-C8)hydrocarbyl;
- Rx is —H, —(C1-C8)hydrocarbyl or (—C-0)(C1-C8)hydrocarbyl;
- Ry is selected from the group consisting of —H, —(C1-C8)hydrocarbyl, —O(C1-C8)hydrocarbyl, substituted phenyl, substituted heterocyclyl(C1-C3)alkyl, heteroaryl(C1-C3)alkyl, —C2-C10)heteroalkyl, —(C1-C6)haloalkyl, —C(Rz)NHRx, —N(Rw)Rx, —(C1-C3)alkyleneNH2, —(C1-C3)alkyleneN(CH3)2, —(C1-C3)perfluoroalkyleneN(CH3)2, —(C1-C3)alkyleneN+(C1-C3)3, —(C1-C3)alkylene-N+(CH2CH2OH)3, —(C1-C3)alkylene-ORx, —(C1-C4)alkylene-CO2Rw, —(C1-C4)alkylene-CO2N(Rw), —(C1-C4)alkylene-C(═O)halogen, halo(C1-C3)alkyl and —(C1-C4)perfluoroalkylene-CO2Rx;
- Rz is selected from the group consisting of —H, —(C1-C6)alkyl, —(CH2)3—NH—C(NH2)(═NH), —CH2C(═O)NH2, —CH2COOH, —CH2SH, —(CH2)2C(═O)—NH2, —(CH2)2CO2H, —CH2-(2-imidazolyl), —(CH2)4—NH2, —(CH2)2—S—CH3, phenyl, —CH2-phenyl, —CH2—OH, —CH(OH)—CH3, —CH2-(3-indolyl) and —CH2-(4-hydroxyphenyl);
- R is —H or —(C1-C7)hydrocarbyl;
- n is 0, 1, 2, 3 or 4;
- and
- R3 is selected from the group consisting of —H and —(C1-C6)alkyl, or a salt of such a compound.
9 more elements
A compound according to Formula IV:
- wherein:
- A is N or CH;
- R2 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl;
- R3 is selected from the group consisting of —H and —(C1-C6)alkyl;
- and
- R is —H or —(C1-C7)hydrocarbyl, or a salt of such a compound.
3 more elements
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound and a compound according to Formula I:
- wherein:
- each Q is independently O, S, or NH;
- each R1 is independently selected from the group consisting of halogen, —(C1-C8)hydrocarbyl, —C(═O)Ry, —N(Rw)2, —N(Rw)C(═O)Ry, —N(Rw)C(Rz)C(═O)Ry, —N(Rw)SO2Ry, —N(Rw)(C1-C4)alkylene-CO2Rw, —NO2, —CN, —ORw, —OC(═O)Ry, —OC(Rz)C(═O)Ry, —OSO2Ry—O(C1-C4)alkylene-CO2Rw, —OP(═O)(ORw)2, —O(C2-C6)alkylene-N(CH3)2, —O(C1-C6)haloalkyl, —P(═O)(ORw)2, —SO2N(R)Rx, —NHC(═NH)NHRx, —(C1-C6)haloalkyl and heteroalkyl;
- Rw is —H or —(C1-C8)hydrocarbyl;
- Rx is —H, —(C1-C8)hydrocarbyl or —C(═O)(C1-C8)hydrocarbyl;
- Ry is selected from the group consisting of —H, —(C1-C8)hydrocarbyl, —O(C1-C8)hydrocarbyl, substituted phenyl, substituted heterocyclyl(C1-C3)alkyl, heteroaryl(C1-C3)alkyl, —(C2-C10)heteroalkyl, —(C1-C6)haloalkyl, —C(Rz)NHRx, —N(Rw)Rx, —(C1-C3)alkyleneNH2, —(C1-C3)alkyleneN(CH3)2, —(C1-C3)perfluoroalkyleneN(CH3)2, —(C1-C3)alkyleneN+(C1-C3)3, —(C1-C3)alkylene-N+(CH2CH2OH)3, —(C1-C3)alkylene-ORx, —(C1-C4)alkylene-CO2Rx, —(C1-C4)alkylene-CO2N(Rw)Rx, —(C1-C4)alkylene-C(═O)halogen, halo(C1-C3)alkyl and —(C1-C4)perfluoroalkylene-CO2Rx;
- Rz is selected from the group consisting of —H, —(C1-C6)alkyl, —(CH2)3—NH—C(NH2)(═NH), —CH2C(═O)NH2, —CH2COOH, —CH2SH, —(CH2)2C(═O)—NH2, —(CH2)2CO2H, —CH2-(2-imidazolyl), —(CH2)4—NH2, —(CH2)2—S—CH3, phenyl, —CH2-phenyl, —CH2—OH, —CH(OH)—CH3, —CH2-(3-indolyl) and —CH2-(4-hydroxyphenyl);
- each n is independently selected from the group consisting of 0, 1, 2, 3 and 4;
- M is selected from the group consisting of a single bond and (a), (b) and (c):
- A is N or CH;
- R2 is substituted or unsubstituted aryl other than unsubstituted phenyl or substituted or unsubstituted heteroaryl;
- R3 is selected from the group consisting of —H and —(C1-C6)alkyl;
- m is 0 or 1;
- provided that:
- (i) when M is a single bond, then R2 is:
- (ii) when M is (c) and m is 0, then R2 is:
- (iii) when M is (b), then n is other than 0, R1 is other than 7-NRw2, and R2 is other than 4-alkoxyphenyl;
- and
- (iv) when M is (a) and Q is O, then R1 is other than —NRw2 and n is other than 0;
- or a pharmaceutically-acceptable salt of such a compound.
17 more elements
Dependencies are inferred from the claim text.